Encouraging findings from this sham-controlled study of the Carillon device for transvenous mitral annuloplasty in functional mitral regurgitation pique interest in the large ongoing CARILLON trial.
Group Classes for Heart Failure Patients: Do They Reduce Hospital Readmissions?
The data is showing some positive results, and the nursing team continues to examine if group education for heart failure patients might improve outcomes. There are many factors.
Heart Failure and Electrophysiology Care by the Numbers (Infographic)
Looking for benchmarks for heart failure or arrhythmia care? Check out some of our latest volume and outcome data in these areas via this dynamic infographic.
More Than a Process Thing: Frontline Lessons in Cardiovascular Quality Improvement
Quality improvement successes don’t just happen but instead result from core principles and best practices. A QI leader shares secrets behind recent quality successes in STEMI care, heart failure and more.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Checking in with the HFSA’s New President, Dr. Randall C. Starling
The veteran heart failure cardiologist shares his goals as president, why he thinks his subspecialty is so dynamic these days and what he most wishes other specialists recognized about heart failure care.
Technology Is Improving Accessibility to Patient Vitals
Heart failure and stepdown units of the Sydell and Arnold Miller Family Heart & Vascular Institute have been testing electrocardiogram technology.
Meet Our New Heart Failure Section Head, Dr. Jerry Estep
The national PI of the ROADMAP trial shares his passion for VADs, current research projects that excite him and why he made a mid-career move to Cleveland Clinic.
What’s on the Horizon in Heart Failure Care and LVAD Technology?
Our experts share eight trends and developments that excite them most in mechanical circulatory support and beyond.
Enzyme Protects Heart Against Stress and Could Potentially Lead to New Heart Failure Treatments
Part of the paraoxynase family, PON2 is produced in the heart and appears to safeguard the organ from stressors.
MitraClip Drives Down Deaths, HF Hospitalization in Secondary Mitral Regurgitation
The COAPT trial finds transcatheter mitral valve repair to be safe and highly effective in a setting with no good treatment options: symptomatic mitral regurgitation secondary to heart failure.